Update your browser

Your browser (Internet Explorer) is out of date.

Update your browser for more security, comfort and the best experience on this site.

CytRx Corporation

CytRx Corporation is a clinical-stage, biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer.

11726 San Vicente Blvd., Suite 650, Los Angeles, CA 90049, United States

Profile Navigation
This is a community generated profile. If you would like to claim it, please contact us.

About

Our Company

CytRx's initial focus is on seeking regulatory approval for and commercialization of our lead drug candidate, aldoxorubicin, an improved version of the widely used chemotherapeutic agent doxorubicin. Aldoxorubicin is currently in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, and is also being evaluated in several other cancer indications with significant unmet clinical need, including small-cell lung cancer.

CytRx plans to expand its pipeline of oncology candidates using its Linker Activated Drug Release, or LADR™, technology platform. Our LADR research efforts currently center on creating new molecules from the combination of ultra high potency cytotoxic payloads with novel, tunable linkers.

Markets

areas of proficiency

Company Type

Choose Company Type

Cancel

Company Size

< 10

Choose Company Size

Cancel

Contact Info

get in touch

  • Location:

    Other: 11726 San Vicente Blvd., Suite 650, Los Angeles, CA 90049, United States